Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tumor suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10) is frequently downregulated in human cancers, but its regulation mechanisms remain unclear.
• The oncogenic role of phosphatase of regenerating liver 2 (PRL2) has been suggested, but the underlying molecular mechanisms are not fully understood.

Purpose of the Study:

• To elucidate the mechanism by which PRL2 contributes to oncogenesis.
• To investigate the relationship between PRL2 and PTEN in cancer development.
• To explore the therapeutic potential of targeting PRL2.

Main Methods:

• Utilized PRL2 ablation models in PTEN heterozygosity-induced tumorigenesis.
• Assessed PTEN levels, AKT signaling, cell proliferation, and apoptosis.
• Correlated PRL2 expression with PTEN levels and patient survival.
• Identified PTEN as a PRL2 substrate and analyzed the dephosphorylation site (Y336).
• Investigated the role of NEDD4-mediated ubiquitination and proteasomal degradation.

Main Results:

• PRL2 ablation inhibited PTEN heterozygosity-induced tumorigenesis.
• PRL2 deficiency led to elevated PTEN levels, attenuated AKT signaling, decreased proliferation, and increased apoptosis.
• High PRL2 expression correlated with low PTEN levels and reduced patient survival.
• PRL2 directly dephosphorylates PTEN at Y336, promoting its ubiquitination and degradation by NEDD4.
• PRL2's ability to downregulate PTEN provides a mechanism for its oncogenic activity.

Conclusions:

• PRL2 downregulates PTEN tumor suppressor by dephosphorylation, leading to increased cancer cell proliferation and survival.
• Targeting PRL2 represents a potential therapeutic strategy to restore PTEN levels and combat PTEN deficiency-driven malignancies.